Supériorité du sécukinumab comparativement à l’ustékinumab évaluée d’après le blanchiment des lésions chez des sujets atteints de psoriasis en plaques modéré à sévère : résultats de l’étude CLEAR à 16 semaines
M. Ruer‐Mulard, Lucie Martin(Novartis (France)), Külli Kingo(Tartu University Hospital), M. Beylot‐Barry(Université de Bordeaux), Andreas Pinter(Goethe University Frankfurt), M. Milutinovic(Novartis (Switzerland)), Tsen‐Fang Tsai(National Taiwan University Hospital), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), F. Vanaclocha(Research Institute Hospital 12 de Octubre), Andrew Blauvelt(Veterans Health Administration), A. Khemis(Hôpital l'Archet), Diamant Thaçi(University of Lübeck), Kristian Reich(Dermatologikum Hamburg), Sophie Hugot(Novartis (Switzerland)), P. Celérier(Centre Hospitalier de La Rochelle)
Cited by 0
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
|Clinical Reviews in Allergy & Immunology|2018|738